Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 114

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Facioscapulohumeral muscular dystrophy

Not recruiting

Study on AOC 1020 for Adults with Facioscapulohumeral Muscular Dystrophy (FSHD)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dux4 Mrna Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Early onset familial Alzheimer's disease

Not recruiting

Study on the Safety and Effects of ABBV-916 and MK-6240 for Patients with Early Alzheimer's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Tourette's disorder

Not recruiting

Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette's Disorder

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ecopipam Hydrochloride
  • Sponsor:Emalex Biosciences Inc.

Atypical haemolytic uraemic syndrome+1

Not recruiting

Study on Ravulizumab for Children with Paroxysmal Nocturnal Hemoglobinuria or Atypical Hemolytic Uremic Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Cerebrovascular accident+1

Not recruiting

Study on Brain Inflammation in Stroke Patients Using Ficolin-2, Gadoteric Acid, and 18F-DPA-714

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid
  • Sponsor:Hospices Civils De Lyon

Hepatic encephalopathy

Not recruiting

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rifaximin
  • Sponsor:Salix Pharmaceuticals Inc.

Orthostatic hypotension

Not recruiting

Study on Ampreloxetine and Midodrine Hydrochloride for Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ampreloxetine
  • Sponsor:Theravance Biopharma Ireland Limited

Autism spectrum disorder

Not recruiting

Study on the Effects of Pitolisant for Children and Adolescents with Autism Spectrum Disorder

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Pitolisant
  • Sponsor:Bioprojet Pharma

Relapsing multiple sclerosis

Not recruiting

Study on the Safety and Efficacy of BIIB091 and Diroximel Fumarate for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Diroximel Fumarate
  • Sponsor:Biogen Idec Research Limited

Dementia Alzheimer's type

Not recruiting

Study on the Safety and Effects of BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Biogen Idec Research Limited

Magnetic resonance imaging+1

Not recruiting

Study Comparing Gadoquatrane with Gadoteric Acid, Gadoteridol, and Gadobutrol for MRI in Patients with Non-CNS Conditions

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Isodicentric chromosome 15 syndrome+3

Not recruiting

Study on Long-Term Safety of Soticlestat for Adults and Children with Developmental Epileptic Encephalopathies

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Soticlestat
  • Sponsor:Takeda Development Center Americas Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.